1. Search Result
Search Result
Results for "

glucose oxidation

" in MedChemExpress (MCE) Product Catalog:

20

Inhibitors & Agonists

2

Screening Libraries

3

Biochemical Assay Reagents

2

Peptides

7

Natural
Products

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-125863

    Endogenous Metabolite Metabolic Disease Cancer
    Glucose-6-phosphate dehydrogenase, Microorganism is the rate-limiting enzyme of the pentose phosphate pathway. Glucose-6-phosphate dehydrogenase is a major source of NADPH that is required by many essential cellular systems including the antioxidant pathways, nitric oxide synthase, NADPH oxidase, cytochrome p450 system, and others. Glucose-6-phosphate dehydrogenase can be used for the research of diabetes, aldosterone-induced endothelial dysfunction, and cancer .
    Glucose-6-phosphate dehydrogenase, Microorganism
  • HY-N9429

    Others Metabolic Disease
    6-Deoxy-D-glucose is an inhibitor of glucose oxidation. 6-Deoxy-D-glucose is a structural homomorph of D-glucose, and can be used for study of D-glucose transport .
    6-Deoxy-D-glucose
  • HY-N8522

    Others Metabolic Disease
    9,10-Dihydroxystearic acid is an oxidation product of oleic acid. 9,10-Dihydroxystearic acid can improve glucose tolerance and insulin sensitivity in KKAy mice .
    9,10-Dihydroxystearic acid
  • HY-N3426

    NO Synthase Akt AMPK Metabolic Disease
    Kazinol B, a prenylated flavan with a dimethyl pyrane ring, is an inhibitor of nitric oxide (NO) production. Kazinol B improves insulin sensitivity by enhancing glucose uptake via the insulin-Akt signaling pathway and AMPK activation. Kazinol B has the potential for diabetes mellitus research .
    Kazinol B
  • HY-N2628

    Others Metabolic Disease
    Erigeroside is as a derivatives of -glucose extracted from Satureja khuzistanica Jamzad. Erigeroside has good ability of anti-oxidation and scavenging oxidation free radical .
    Erigeroside
  • HY-P3186

    Endogenous Metabolite Metabolic Disease
    Glucose dehydrogenase, recombinant Microorganisms is a oxidoreductase. Glucose dehydrogenase (GDH) catalyzes the oxidation of β-D-glucose to β-D-glucono-1,5-lactone with simultaneous reduction of the cofactor NADP + to NADPH or, to a lesser extent, NAD + to NADH. Glucose dehydrogenase (GDH) accepts both NAD + and NADP + as cofactors and can be used for the regeneration of NADH and NADPH .
    Glucose dehydrogenase, recombinant Microorganisms
  • HY-130319A

    PPAR Cardiovascular Disease Metabolic Disease
    9-HEPE, a oxidation product of Eicosapentaenoic acid, is a racemic mixture of 9(R)-HEPE and 9(S)-HEPE. 9-HEPE induces fatty acid oxidation, adipogenesis, and glucose uptake via activation of PPARs in vivo .
    9-HEPE
  • HY-P1184

    Reactive Oxygen Species Cardiovascular Disease Neurological Disease Metabolic Disease
    HNGF6A is a humanin analogue. HNGF6A increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A inhibits of ROS production during oxidative stress. HNGF6A can prevent endothelial dysfunction and atherosclerosis in vivo .
    HNGF6A
  • HY-P1184A

    Reactive Oxygen Species Cardiovascular Disease Neurological Disease Metabolic Disease
    HNGF6A TFA is a humanin analogue. HNGF6A TFA increases glucose-stimulated insulin secretion and glucose metabolism, and has the potential for diabetes research. HNGF6A TFA inhibits of ROS production during oxidative stress. HNGF6A TFA can prevent endothelial dysfunction and atherosclerosis in vivo .
    HNGF6A TFA
  • HY-A0231

    Gondafon; Glycodiazine

    Glymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization .
    Glymidine sodium
  • HY-139577

    IMB-1018972; IMB-101

    Mitochondrial Metabolism Metabolic Disease Cancer
    Ninerafaxstat (IMB-1018972) is a novel mitotropic agent. Ninerafaxstat increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat can be used for the research of cardiovascular diseases .
    Ninerafaxstat
  • HY-139577A

    MB-1018972 trihydrochloride; IMB-101 trihydrochloride

    Mitochondrial Metabolism Metabolic Disease Cancer
    Ninerafaxstat (IMB-1018972) trihydrochloride is a novel mitotropic agent. Ninerafaxstat trihydrochloride increases myocardial metabolic efficiency by shifting substrate utilization towards glucose through reducing fatty acid oxidation (inhibiting 3-ketoacyl CoA thiolase). Ninerafaxstat trihydrochloride can be used for the research of cardiovascular diseases .
    Ninerafaxstat trihydrochloride
  • HY-126415

    Others Cardiovascular Disease Neurological Disease Inflammation/Immunology
    Magnesium Lithospermate B, a derivative of caffeic acid tetramer, and is extracted from Salviae miltiorrhizae. Magnesium Lithospermate B is widely used for the research of cardiovascular diseases, and it can protect against glucose-induced intracellular oxidative damage. Magnesium Lithospermate B also suppresses neuroinflammation and attenuates neurodegeneration .
    Magnesium Lithospermate B
  • HY-149405

    Others Metabolic Disease
    Squalene synthase-IN-1 (compound 1) is a potent antihyperlipidemic agent acting through Squalene Synthase inhibition. Squalene synthase-IN-1 exhibits an outstanding antioxidant and anti-inflammatory activity. Squalene synthase-IN-1 displays a significant reduction not only of glucose but also of oxidative stress levels, while it did not cause any toxicity .
    Squalene synthase-IN-1
  • HY-129297

    Endogenous Metabolite Metabolic Disease
    CMPF can be found in trace constituent of urine and blood. CMPF is a biomarker of type 2 diabetes. CMPF can act on the β cell and induces impaired mitochondrial function. CMPF decreases glucose-induced ATP accumulation, and induces oxidative stress. CMPF reverses hepatic lipid accumulation and improves insulin sensitivity in obese mice .
    CMPF
  • HY-145963

    GLUT Cancer
    DRB18 is a potent pan-class GLUT inhibitor. DRB18 alters energy-related metabolism in A549 cells by changing the abundance of metabolites in glucose-related pathways. DRB18 can eventually lead to G1/S phase arrest and increase oxidative stress and necrotic cell death. DRB18 has anti-tumor activity .
    DRB18
  • HY-W127499

    DEPC; L-Dierucoyl lecithin; Dierucoyllecithin

    Liposome Others
    1,2-Dierucoyl-sn-glycero-3-phosphocholine (DEPC) is the composition of liposome membrane. 1,2-Dierucoyl-sn-glycero-3-phosphocholine is used for the preparation of liposomes and studying the properties of lipid bilayers. The GO (glucose oxidase) in the 1,2-Dierucoyl-sn-glycero-3-phosphocholine liposome shows the high activity .
    1,2-Dierucoyl-sn-glycero-3-phosphocholine
  • HY-108458

    TRP Channel Inflammation/Immunology
    SB 452533 is a potent and selective TRPV1 antagonist with the pKb of 7.8 .
    SB 452533
  • HY-W142618

    Biochemical Assay Reagents Others
    D-Glucal is an organic compound belonging to the family of aldoses, which are monosaccharides containing an aldehyde functional group. It has a six-carbon structure and is derived from glucose by oxidation of the primary alcohol group at carbon 1 to an aldehyde group. D-Glucal is a white crystalline solid that is soluble in water and has a sweet taste. It is an important intermediate in the chemical synthesis of a wide variety of compounds, including pharmaceuticals, agrochemicals, and natural products. D-Glucal can be converted into other carbohydrate derivatives such as glycosides, glycoconjugates and amino sugars. It also plays a role in the study of carbohydrate chemistry, where it is used as a chiral building block for the synthesis of complex structures.
    D-Glucal
  • HY-121744
    PS10
    2 Publications Verification

    PDHK Inflammation/Immunology
    PS10 is a novel, potent and ATP-competitive pan-PDK inhibitor, inhibits all PDK isoforms with IC50 of 0.8 μM, 0.76 μM, 2.1 μM and 21.3 μM for PDK2, PDK4, PDK1, and PDK3, respectively. PS10 shows high affinity for PDK2 (Kd= 239 nM) than for Hsp90 (Kd= 47 μM) . PS10 improves glucose tolerance, stimulates myocardial carbohydrate oxidation in diet-induced obesity. PS10 has the potential for the investigation of diabetic cardiomyopathy .PDK: pyruvate dehydrogenase kinase
    PS10

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: